Filter
614
Text search:
FDA
Featured
Recommendations
81
New Publications
121
Language
Document type
No document type
303
Guidelines
160
Studies & Reports
75
Manuals
24
Fact sheets
24
Strategic & Response Plan
13
Training Material
7
Resource Platforms
3
Brochures
2
Situation Updates
2
Infographics
1
Countries / Regions
India
29
Ghana
17
Latin America and the Carribbean
17
Russia
17
Philippines
12
Myanmar / Burma
12
South Africa
9
Middle East and North Africa
9
USA
8
Kenya
8
Brazil
8
Global
8
Nigeria
7
Congo, Democratic Republic of
7
Germany
7
Syria
7
Argentina
7
West and Central Africa
7
Senegal
6
Uganda
6
Ukraine
6
Colombia
6
Ecuador
6
Yemen
6
Western and Central Europe
6
South Sudan
5
Angola
5
Paraguay
5
Eastern Europe
5
Burkina Faso
4
Liberia
4
Mali
4
Ethiopia
4
Indonesia
4
Mozambique
4
Sudan
4
Peru
4
Eastern Europe and Central Asia
4
Guinea
3
Sierra Leone
3
Nepal
3
Tanzania
3
Thailand
3
Bangladesh
3
Bolivia
3
East and Southern Africa
3
South–East Asia Region
3
Africa
3
Venezuela
3
France
3
Guinea-Bissau
2
Côte d’Ivoire / Ivory Coast
2
Niger
2
Haiti
2
Iraq
2
Jordan
2
Rwanda
2
Namibia
2
El Salvador
2
Chile
2
Asia
2
Albania
2
Tajikistan
2
Morocco
1
Saudi Arabia
1
Cameroon
1
Zimbabwe
1
Somalia
1
Lebanon
1
Egypt
1
Chad
1
Cambodia
1
Mauritania
1
Singapore
1
Malawi
1
Benin
1
Dominican Republic
1
Cuba
1
Honduras
1
Botswana
1
Libya
1
Guatemala
1
Madagascar
1
Mexico
1
Nicaragua
1
Armenia
1
Congo-Brazzaville
1
Qatar
1
Moldova
1
Kazakhstan
1
Tunisia
1
Spain
1
Belarus
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
190
Clinical Guidelines
80
Pharmacy & Technologies
22
Women & Child Health
17
Public Health
11
Key Resources
8
Capacity Building
2
Toolboxes
COVID-19
136
Mental Health
69
TB
59
HIV
48
Pharmacy
35
AMR
30
Ebola
28
Rapid Response
17
Specific Hazards
13
NTDs
10
Zika
8
Refugee
7
NCDs
7
Planetary Health
6
Cholera
3
Conflict
3
Natural Hazards
3
Caregiver
3
Global Health Education
2
Disability
1
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons
...
El grupo de Farmacovigilancia de la red Panamericana para la Armonización Farmacéutica (PARF) de la Organización Panamericana de la Salud (OPS), ha desarrollado este documento desde la visión OPS/OMS, considerando que la farmacovigilancia es un componente esencial de los programas de salud públ
...
Guía de medicamentos esenciales para primer nivel de atención – Edición 2019
Las guías para la prevención de Infecciones del Sitio Quirúrgico (ISQ) resumen las medidas basadas en la evidencia que han demostrado disminuir su incidencia y mejorar la calidad asistencial de los pacientes sometidos a cirugía. La última revisión local fue realizada en el año 2009, en el mar
...
Accessed on 16.08.2022
Para ello integra:
• Las 36 recomendaciones sobre diabetes mellitus tipo 2:
1. Rastreo y diagnóstico.
2. Prevención.
3. Educación diabetológica para el automanejo.
4. Metas de control glucémico.
5. Tratamiento: estilo de vida saludable y tratamiento farmacoló
...
Therapeutics for Ebola virus disease
recommended
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il
...
Traitements contre la maladie à virus Ebola
recommended
Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico
...
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing. These priority areas are:
...
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t
...
This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts and WHO support to Member States. Regular collection and analysis of da
...
This document outlines the working structure and guiding principles for collaboration of COVAX, the Vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A). The working structure of COVAX continues to adapt to emerging needs and the changing trajectory of the pandemic. Some components of
...
Front Chem. 2021; 9: 622286.
Published online 2021 Mar 12. doi: 10.3389/fchem.2021.622286
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach
...
Ce rapport présente une analyse de l'OMS sur les pénuries et le manque de disponibilité des antibiotiques hors brevet en France prenant en compte l'approche Une seule santé. Le rapport est organisé en deux sections : santé animale et santé humaine.
Le rapport vise à donner un éclairage sur
...
April 2022 Volume 35 Issue 2 e00152-21
Population movements have turned Chagas disease (CD) into a global public health problem. Despite the successful implementation of subregional initiatives to control vectorial and transfusional Trypanosoma cruzi transmission in Latin American settings where t
...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f
...
Epidemiology
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or
...
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or drink.1-4 The
...
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita
...
Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani
...
